- Previous Close
0.3499 - Open
0.3610 - Bid --
- Ask --
- Day's Range
0.3500 - 0.3649 - 52 Week Range
0.2030 - 4.0600 - Volume
1,508,016 - Avg. Volume
1,032,815 - Market Cap (intraday)
12.66M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4200 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
nkgenbiotech.comRecent News: NKGN
View More
Performance Overview: NKGN
Trailing total returns as of 10/29/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKGN
View MoreValuation Measures
Market Cap
12.38M
Enterprise Value
40.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-106.84%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-88.25M
Diluted EPS (ttm)
-3.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
79k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
12.75M
Company Insights: NKGN
NKGN does not have Company Insights